Psoriatic Arthritis

Tofacitinib Efficacy Investigated in Patients With Psoriatic Arthritis

October 20, 2017

Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs

Stelara Approved to Treat Adolescent Patients With Plaque Psoriasis

By October 16, 2017

The expanded approval was supported by data from a Phase 3 study that evaluated the safety and efficacy of subcutaneous Stelara in adolescents aged ≥12 years.

Biosimilar Cyltezo Gets FDA Approval for Multiple Indications

By August 28, 2017

This marks the second approval of a biosimilar for adalimumab.

Psoriatic Arthritis Treatment Trends Investigated

By August 15, 2017

Researchers used claims data between 2004-2015 from a large commercial database to identify patients with psoriatic arthritis who were initiated on DMARDs.

FDA Panel Recommends Approval of Tofacitinib for Psoriatic Arthritis

By August 04, 2017

The supplemental New Drug Applications (sNDAs) contained data from Phase 3 trials involving patients with psoriatic arthritis, including safety analyses from the larger tofacitinib clinical development program.

Ixekizumab Beneficial in Psoriatic Arthritis Refractory to TNFi

May 31, 2017

Two-week and four-week ixekizumab dosing regimens improved signs and symptoms

Patient Develops Psoriatic Arthritis After Multiple Wasp Stings

By December 14, 2016

While rare, cases of arthritis associated with bee and wasp stings have been previously reported in the medical literature.

Tofacitinib Effective in PsA Patients With Prior Inadequate Response

By November 16, 2016

Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study